Proteasome inhibition after burn injury

Journal of Burn Care and Research

Volumn 37, Issue 4, 2016, Pages 207-215

  Vana, P Geoff ^a   Laporte, Heather M ^a   Wong, Yee M ^a   Kennedy, Richard H ^a   Gamelli, Richard L ^a   Majetschak, Matthias ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; BORTEZOMIB; CHOLESTEROL; CREATININE; EPOXOMICIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; NITROGEN; PROTEASOME; PROTEIN; SODIUM; UBIQUITIN; UBIQUITIN PROTEIN CONJUGATE; UNCLASSIFIED DRUG; UREA; PROTEASOME INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTHROPOMETRIC PARAMETERS; BLOOD CHEMISTRY; BLOOD SAMPLING; BODY SURFACE; BODY WEIGHT; BURN; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; HYPERMETABOLISM; MALE; MORTALITY RATE; MUSCLE BIOPSY; NONHUMAN; PECTORAL MUSCLE; RAT; RESTING ENERGY EXPENDITURE; SCALD; SHAM PROCEDURE; SURVIVAL TIME; TREATMENT DURATION; ANIMAL; BASAL METABOLIC RATE; SPRAGUE DAWLEY RAT;

ANIMALS; BASAL METABOLISM; BODY WEIGHT; BORTEZOMIB; BURNS; MALE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84978066707     PISSN: 1559047X     EISSN: 15590488     Source Type: Journal    
DOI: 10.1097/BCR.0000000000000280     Document Type: Conference Paper

References (45)

1. Pereira C, Murphy K, Jeschke M, Herndon DN. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol 2005; 37: 1948-61
2. Hart DW, Wolf SE, Chinkes DL, et al. Determinants of skeletal muscle catabolism after severe burn. Ann Surg 2000; 232: 455-65
3. Garcia de Lorenzo y Mateos A, Ortiz Leyba C, Sanchez SM. Guidelines for specialized nutritional and metabolic support in the critically-ill patient: update. Consensus SEMICYUC-SENPE: critically-ill burnt patient. Nutr Hosp 2011; 26: (Suppl 2): 59-62
4. Williams FN, Herndon DN, Jeschke MG. The hypermetabolic response to burn injury and interventions to modify this response. Clin Plast Surg 2009; 36: 583-96
5. Porter C, Hurren NM, Herndon DN, Børsheim E. Whole body and skeletal muscle protein turnover in recovery from burns. Int J Burns Trauma 2013; 3: 9-17
6. Matsuda T, Clark N, Hariyani GD, Bryant RS, Hanumadass ML, Kagan RJ. The effect of burn wound size on resting energy expenditure. J Trauma 1987; 27: 115-8
7. Jeschke MG, Gauglitz GG, Kulp GA, et al. Long-Term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011; 6: e21245
8. Wilmore DW, Aulick LH, Mason AD, Pruitt BA Jr. Influence of the burn wound on local and systemic responses to injury. Ann Surg 1977; 186: 444-58
9. Porter C, Herndon DN, Sidossis LS, Børsheim E. The impact of severe burns on skeletal muscle mitochondrial function. Burns 2013; 39: 1039-47
10. Majetschak M, Waydhas C. Infection, bacteremia, sepsis and the sepsis syndrome-metabolic alterations, hypermetabolism, and cellular alterations. In: Baue AE, Faist E, Fry DE, editors. Multiple organ failure: pathophysiology, prevention, and therapy. New York, NY: Springer 2000. p. 101-107
11. Tuvdendorj D, Chinkes DL, Zhang XJ, et al. Long-Term oxandrolone treatment increases muscle protein net deposition via improving amino acid utilization in pediatric patients 6 months after burn injury. Surgery 2011; 149: 645-53
12. Hart DW, Wolf SE, Ramzy PI, et al. Anabolic effects of oxandrolone after severe burn. Ann Surg 2001; 233: 556-64
13. Herndon DN, Ramzy PI, DebRoy MA, et al. Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg 1999; 229: 713-20; discussion 720-2
14. Meyer NA, Barrow RE, Herndon DN. Combined insulin-like growth factor-1 and growth hormone improves weight loss and wound healing in burned rats. J Trauma 1996; 41: 1008-12
15. Biolo G, Fleming RY, Maggi SP, Nguyen TT, Herndon DN, Wolfe RR. Inverse regulation of protein turnover and amino acid transport in skeletal muscle of hypercatabolic patients. J Clin Endocrinol Metab 2002; 87: 3378-84
16. Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992; 61: 761-807
17. Ciechanover A. Intracellular protein degradation from a vague idea through the lysosome and the ubiquitin-proteasome system and on to human diseases and drug targeting: Nobel Lecture, December 8, 2004. Ann N Y Acad Sci 2007; 1116: 1-28
18. Jagoe RT, Goldberg AL. What do we really know about the ubiquitin-proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 2001; 4: 183-90
19. Twombly R. First proteasome inhibitor approved for multiple myeloma. J Natl Cancer Inst 2003; 95: 845
20. Herndon TM, Deisseroth A, Kaminskas E, et al. U.S. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res 2013; 19: 4559-63
21. Walker HL, Mason AD Jr A standard animal burn. J Trauma 1968; 8: 1049-51
22. Cavaletti G, Gilardini A, Canta A, et al. Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat. Exp Neurol 2007; 204: 317-25
23. Nowis D, Maczewski M, Mackiewicz U, et al. Cardiotoxicity of the anticancer therapeutic agent bortezomib. Am J Pathol 2010; 176: 2658-68
24. Blanchaer MC, Van Wijhe M. Isozymes of lactic dehydrogenase in skeletal muscle. Am J Physiol 1962; 202: 827-9
25. Wong YM, La Porte HM, Szilagyi A, et al. Activities of nonlysosomal proteolytic systems in skeletal and cardiac muscle during burn-induced hypermetabolism. J Burn Care Res 2014; 35: 319-27
26. Majetschak M, Patel MB, Sorell LT, Liotta C, Li S, Pham SM. Cardiac proteasome dysfunction during cold ischemic storage and reperfusion in a murine heart transplantation model. Biochem Biophys Res Commun 2008; 365: 882-8
27. Geng Q, Romero J, Saini V, et al A subset of 26S proteasomes is activated at critically low ATP concentrations and contributes to myocardial injury during cold ischemia. Biochem Biophys Res Commun 2009; 390: 1136-41
28. Majetschak M, Sorell LT. Immunological methods to quantify and characterize proteasome complexes: development and application. J Immunol Methods 2008; 334: 91-103
29. Patel MB, Majetschak M. Distribution and interrelationship of ubiquitin proteasome pathway component activities and ubiquitin pools in various porcine tissues. Physiol Res 2007; 56: 341-50
30. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 1999; 96: 10403-8
31. Baker TA, Geng Q, Romero J, Picken MM, Gamelli RL, Majetschak M. Prolongation of myocardial viability by proteasome inhibition during hypothermic organ preservation. Biochem Biophys Res Commun 2010; 401: 548-53
32. Khorram-Sefat R, Behrendt W, Heiden A, Hettich R. Longterm measurements of energy expenditure in severe burn injury. World J Surg 1999; 23: 115-22
33. Fang CH, Li BG, Fischer DR, et al. Burn injury upregulates the activity and gene expression of the 20 S proteasome in rat skeletal muscle. Clin Sci (Lond) 2000; 99: 181-7
34. Ni B, Zhou J, Dong Y, et al. Interleukin-1 up-regulates the expression and activity of 26S proteasome in burned rat. Burns 2007; 33: 621-7
35. Hamilton AL, Eder JP, Pavlick AC, et al. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle. J Clin Oncol 2005; 23: 6107-16
36. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22
37. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16
38. Wolfe RR. Review: acute versus chronic response to burn injury. Circ Shock 1981; 8: 105-15
39. Tredget EE, Yu YM. The metabolic effects of thermal injury. World J Surg 1992; 16: 68-79
40. Reinstein E. Immunologic aspects of protein degradation by the ubiquitin-proteasome system. Isr Med Assoc J 2004; 6: 420-4
41. Mohty M, Brissot E, Savani BN, Gaugler B. Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant 2013; 19: 1416-20
42. Nencioni A, Grunebach F, Patrone F, Ballestrero A, Brossart P. The proteasome and its inhibitors in immune regulation and immune disorders. Crit Rev Immunol 2006; 26: 487-98
43. Ronnebaum SM, Patterson C, Schisler JC. Minireview: hey U(PS): metabolic and proteolytic homeostasis linked via AMPK and the ubiquitin proteasome system. Mol Endocrinol 2014; 28: 1602-15
44. Sharpe LJ, Cook EC, Zelcer N, Brown AJ. The UPS and downs of cholesterol homeostasis. Trends Biochem Sci 2014; 39: 527-35
45. Zhang F, Paterson AJ, Huang P, Wang K, Kudlow JE. Metabolic control of proteasome function. Physiology (Bethesda) 2007; 22: 373-9